E-PaperInd Swift Q3 FY24 Results Live: Loss Rise by 1350.11% YoY
Ind Swift Q3 FY24 Results Live: Revenue Decreased by 3.78% YoY & Loss Increased by 1350.11% YoY
Ind Swift, a pharmaceutical company, has declared their Q3 FY24 results on 14 Feb, 2024.
The topline of the company has decreased by 3.78% compared to the same quarter last year.
Furthermore, the company has witnessed a staggering increase of 1350.11% in their loss YoY.
In comparison to the previous quarter, the revenue declined by 11.52% and the loss increased by 39.79%.
The Selling, general & administrative expenses of Ind Swift rose by 9.89% quarter-on-quarter and increased by 12.8% year-on-year.
The operating income of the company was down by 151.94% quarter-on-quarter and decreased by 121.59% year-on-year.
The EPS for Q3 FY24 is ₹-2.76, which indicates a decrease of 1352.63% year-on-year.
In terms of returns, Ind Swift has delivered -6.39% return in the last 1 week, 31.83% return in the last 6 months, and 4.67% year-to-date return.
Currently, Ind Swift has a market cap of ₹103.18 Cr and a 52-week high/low of ₹23.75 & ₹6.6 respectively.
Ind Swift Financials
| Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 102.56 | 115.92 | -11.52% | 106.59 | -3.78% |
| Selling/ General/ Admin Expenses Total | 20.46 | 18.61 | +9.89% | 18.13 | +12.8% |
| Depreciation/ Amortization | 6.78 | 6.73 | +0.63% | 7.29 | -7.03% |
| Total Operating Expense | 104.85 | 111.51 | -5.97% | 95.98 | +9.24% |
| Operating Income | -2.29 | 4.41 | -151.94% | 10.6 | -121.59% |
| Net Income Before Taxes | -14.97 | -10.71 | -39.79% | -1.03 | -1350.11% |
| Net Income | -14.97 | -10.71 | -39.79% | -1.03 | -1350.11% |
| Diluted Normalized EPS | -2.76 | -1.98 | -39.39% | -0.19 | -1352.63% |
- Top Gainers
- Top Losers
- 52 Week High
